Publications by authors named "M Sarocchi"
Article Synopsis
- Repeated blood transfusions can lead to iron overload, negatively affecting heart function in patients with myelodysplastic syndromes (MDS), and iron chelation therapy like deferasirox may help prevent this damage.
- The TELESTO study found that patients treated with deferasirox had a significantly lower risk of hospitalization for heart failure or worsening heart function compared to those on a placebo.
- Although deferasirox showed benefits, the study noted that most patients were younger with low cardiovascular risk and had no major heart issues, making the identification of those developing heart failure difficult.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the management of multiple tumors, due to improved efficacy, quality of life, and safety. While most immune-related adverse events (irAEs) are mild and easily managed, in rare cases such events may be life-threatening, especially those affecting the neuromuscular and cardiac system. The management of neuromuscular/cardiac irAEs is not clear due to the lack of consistent data.
View Article and Find Full Text PDFPurpose Of The Review: Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD).
View Article and Find Full Text PDFBackground: the European Society of Cardiology Heart Failure Association (HFA) together with the International Cardio-Oncology Society (ICOS) proposed charts for baseline CV risk assessment of cancer patients scheduled to receive anthracyclines and anti-human epidermal growth factor receptor-2 (HER2) agents.
Methods: We investigated HFA/ICOS risk stratification, prescriptions of cardioactive drugs, and occurrence of CV events in a multicentric breast cancer (BC) cohort from 3 Italian Outpatient Cardio-Oncology Clinics.
Results: 373 BC patients who underwent a baseline Cardio-Oncologic evaluation were included, of whom 202 scheduled to receive anthracyclines and 171 anti-HER2.